Benefits of heart failure-specific pharmacotherapy in frail hospitalised patients: a cross-sectional study

OBJECTIVES: Up to 50% of heart failure (HF) patients may be frail and have worse clinical outcomes than non-frail patients. The benefits of HF-specific pharmacotherapy (beta-blockers, ACE-inhibitors/angiotensin-receptor-blockers and mineralocorticoid-receptor-antagonist) in this population are uncle...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Yogesh, Horwood, Chris, Hakendorf, Paul, Thompson, Campbell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486223/
https://www.ncbi.nlm.nih.gov/pubmed/36123054
http://dx.doi.org/10.1136/bmjopen-2021-059905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486223/
https://www.ncbi.nlm.nih.gov/pubmed/36123054
http://dx.doi.org/10.1136/bmjopen-2021-059905

Ejemplares similares